No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARCT240621C50000
- 0.35
- 0.000.00%
15min DelayTrading Jun 7 15:39 ET
0.00High0.00Low
0.00Open0.35Pre Close0 Volume175 Open Interest50.00Strike Price0.00Turnover638.49%IV90.47%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.0838Delta0.0145Gamma75.53Leverage Ratio-0.3450Theta0.0001Rho6.33Eff Leverage0.0026Vega
Intraday
- 5D
- Daily
News
Express News | Arcturus Therapeutics Appoints Moncef Slaoui, Ph.d., to Board of Directors
This Insider Has Just Sold Shares In Arcturus Therapeutics Holdings
Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shareholders may be a little concerned to see that the CFO & Director, Andrew Sassine, recently sold a substantial US$1.6m worth of stock at a pr
Insider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT)
Arcturus Therapeutics(ARCT.US) Officer Sells US$1.6 Million in Common Stock
$Arcturus Therapeutics(ARCT.US)$ Officer SASSINE ANDY sold 50,000 shares of common stock on Jun 12, 2024 at an average price of $32.03 for a total value of $1.6 million.Source: Announcement What is st
Arcturus Therapeutics Holdings Insider Sold Shares Worth $1,601,500, According to a Recent SEC Filing
Andy Sassine, Director, Chief Financial Officer, on June 12, 2024, sold 50,000 shares in Arcturus Therapeutics Holdings (ARCT) for $1,601,500. Following the Form 4 filing with the SEC, Sassine has con
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market
Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving $Robinhood(HOOD.US)$ and $Zoom Video Communications(ZM.US)$.The Robinhood TradeArk Invest sold 64,706 shares of Robinhood
Comments
$Arcturus Therapeutics(ARCT.US$ wtf is happening bout to put this hoe down
Analysts maintain loss per share estimates for next year with no major changes to revenue estimates. However, the company's performance is expected to underperform the wider industry. The steady consensus price target indicates that reduced loss estimates may not positively impact the stock's long-term valuation.
Despite Arcturus Therapeutics Holdings Inc.'s strong run, its P/S ratio remains low due to a weak revenue outlook. Investors believe the potential for revenue improvement doesn't justify a higher P/S ratio, forming a barrier for the share price.
The recent improvement in total shareholder return could indicate that the business is getting better over time. However, there are 2 warning signs that investors should be aware of. The sentiment around the company seems to be positive lately.
Read more